Ascletis Pharma Inc

Ascletis Pharma Inc. is a biotechnology company focused on developing antiviral drugs to address unmet medical needs in various domains, with operations in China and a global presence.

Ascletis Pharma Inc. has announced a major breakthrough in acne treatment with denifanstat, a once-daily oral medication that has shown significant efficacy and safety in a Phase III clinical trial.

Ascletis Pharma Inc. has achieved significant milestones in its drug development pipeline, including IND clearance for ASC50 and the initiation of a clinical study combining ASC47 with semaglutide for obesity treatment.